Cardiac inflammation, an intricate condition involving the inflammation of the heart tissues, emerges as a pivotal factor in various cardiovascular ailments. This inflammatory response can arise from diverse triggers, including infections, autoimmune disorders, or underlying health issues. The consequences of cardiac inflammation are profound, potentially impairing the heart's ability to pump blood efficiently. Notable manifestations such as myocarditis and pericarditis underscore the significance of timely intervention to avert the risk of heart failure. Researchers and healthcare experts are actively delving into the complex mechanisms of cardiac inflammation, aiming to develop precise interventions and preventative strategies. Comprehensive comprehension and effective management of cardiac inflammation stand as imperative measures in advancing cardiovascular health and alleviating the impact of associated diseases on individuals globally.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States